Stockscreener 앱 받기
38.49
1.61%
0.61
시간 외 거래:
39.00
0.51
+1.33%
전일 마감가:
$37.88
열려 있는:
$37.94
하루 거래량:
676.25K
Relative Volume:
1.66
시가총액:
$1.12B
수익:
$219.79M
순이익/손실:
$-57.47M
주가수익비율:
-17.90
EPS:
-2.15
순현금흐름:
$-19.25M
1주 성능:
+13.37%
1개월 성능:
+57.04%
6개월 성능:
+139.07%
1년 성능:
+29.12%
1일 변동 폭
$37.58
$39.62
1주일 범위
$33.03
$39.62
52주 변동 폭
$14.59
$39.62
Castle Biosciences Inc Stock (CSTL) Company Profile
명칭
Castle Biosciences Inc
전화
866-788-9007
주소
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
CSTL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
38.49 | 1.11B | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
586.07 | 220.72B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.98 | 160.62B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
752.14 | 57.96B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
153.60 | 42.88B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
228.18 | 38.30B | 15.90B | 1.28B | 2.21B | 7.2842 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-04-30 | 개시 | Lake Street | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | 재확인 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | BTIG Research | Buy |
| 2019-08-19 | 개시 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | Robert W. Baird | Outperform |
| 2019-08-19 | 개시 | SVB Leerink | Outperform |
모두보기
Castle Biosciences Inc 주식(CSTL)의 최신 뉴스
Top 5 Articles of the Week: November 16-21 - Dermatology Times
Is Pune Es Valuation Cheap Compared to Growth PeersChart Pattern Recognition & Superior Wealth Building - earlytimes.in
Castle Biosciences partners with SciBase for diagnostic tests - MSN
What Makes Castle Biosciences (CSTL) a New Strong Buy Stock - MSN
Castle Biosciences (NASDAQ:CSTL) Sets New 1-Year HighTime to Buy? - MarketBeat
Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable - sharewise.com
Castle Biosciences stock hits 52-week high at $35.68 By Investing.com - Investing.com Canada
[Form 4] CASTLE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Castle Biosciences stock hits 52-week high at $35.68 - Investing.com India
Can Castle Biosciences Inc. stock deliver consistent earnings growthJuly 2025 Institutional & Real-Time Chart Pattern Alerts - newser.com
Castle Biosciences earns Houston Top Workplace title for fifth year - Traders Union
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth - MSN
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Castle Biosciences, Inc. (CSTL) Competitors - Meyka
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year - The Manila Times
Zacks.com featured highlights include Perimeter Solutions, Interface, Castle Biosciences and Great Lakes Dredge & Dock - sharewise.com
Castle Biosciences (Nasdaq: CSTL) Receives 13 Top Workplaces and Culture Excellence Honors - Stock Titan
Castle Biosciences, Inc. $CSTL Shares Sold by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Will Castle Biosciences Inc. stock remain a Wall Street favorite2025 Volatility Report & Reliable Trade Execution Plans - newser.com
Castle Biosciences Inc. recovery potential after sell off2025 Biggest Moves & AI Driven Stock Reports - newser.com
Advisors Capital Management LLC Purchases 44,180 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat
Full technical analysis of Castle Biosciences Inc. stockEarnings Miss & Breakout Confirmation Alerts - newser.com
Is Castle Biosciences Inc. stock a dividend growth opportunity2025 Buyback Activity & Fast Gain Stock Trading Tips - newser.com
Quantitative breakdown of Castle Biosciences Inc. recent moveForecast Cut & Fast Exit/Entry Strategy Plans - newser.com
Is Castle Biosciences Inc a good long term investmentMarket Liquidity Analysis & High Profit Growth Stocks - earlytimes.in
Evaluating Castle Biosciences Inc. with trendline analysisPortfolio Performance Report & High Accuracy Buy Signal Tips - newser.com
Castle Biosciences melanoma test shows improved risk prediction By Investing.com - Investing.com Nigeria
[Form 4/A] CASTLE BIOSCIENCES INC Amended Insider Trading Activity - Stock Titan
Pattern recognition hints at Castle Biosciences Inc. upsideBond Market & Capital Efficient Trading Techniques - newser.com
Why Castle Biosciences Inc. stock could be next big winnerQuarterly Investment Review & AI Powered Buy and Sell Recommendations - Fundação Cultural do Pará
Castle Biosciences (CSTL) Showcases Breakthrough in Melanoma Tes - GuruFocus
Castle Biosciences melanoma test shows improved risk prediction - Investing.com
Castle Biosciences Announces Clinical Data Supporting DecisionDx-Melanoma's Role in Sentinel Lymph Node Biopsy Decision Making at ECDO 2025 - Quiver Quantitative
New Data Confirms Performance of DecisionDx®-Melanoma to - GlobeNewswire
Insider Sell: Frank Stokes Sells Shares of Castle Biosciences In - GuruFocus
Return on assets % of Castle Biosciences, Inc. – FWB:086 - TradingView
Chart based analysis of Castle Biosciences Inc. trends2025 Volume Leaders & Technical Confirmation Trade Alerts - newser.com
Zacks.com featured highlights include Castle Biosciences, Perimeter Solutions, South Atlantic Bancshares and Astronics - sharewise.com
Castle Biosciences, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:CSTL) 2025-11-12 - Seeking Alpha
COO Oelschlager Files To Sell 18,932 Of Castle Biosciences Inc [CSTL] - TradingView
Acadian Asset Management LLC Has $11.11 Million Stock Position in Castle Biosciences, Inc. $CSTL - MarketBeat
Castle Biosciences (NASDAQ:CSTL) Reaches New 52-Week HighHere's Why - MarketBeat
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Is Castle Biosciences Ready To Turn Stability Into Growth? - RTTNews
Castle Biosciences Inc (CSTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.35%
1.41%
자본화:
|
볼륨(24시간):